Overview Dividends

(LH) Laboratory of America - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5049221055

Diagnostics, Testing, Lab, Drug, Health

Health Care Services
Market Cap in USD: 21,195m

IPO / Inception: 1990-03-29
Return 12m vs S&P 500: -4.34%

EPS (Earnings per Share)

EPS CAGR: -12.07%
EPS Trend: -60.9%

Last SUE: 0.98
Qual. Beats: 3

Revenue

Rev. CAGR: -3.39%
Rev. Trend: -4.8%

Last SUE: 0.09
Qual. Beats: 0

Dividends

Dividend Yield	1.13%
Yield on Cost 5y	1.73%
Yield CAGR 5y	15.47%
Payout Consistency	17.2%
Payout Ratio	18.2%

Risk via 5d forecast
Volatility	19.7%
Value at Risk 5%th	30.7%
Relative Tail Risk	-4.99%

Reward TTM
Sharpe Ratio	0.41
Alpha	0.49
CAGR/Max DD	0.54

Character TTM
Hurst Exponent	0.465
Beta	0.602
Beta Downside	0.570

Drawdowns 3y
Max DD	17.36%
Mean DD	6.27%
Median DD	5.75%

Description: LH Laboratory of America December 17, 2025

Labcorp (NYSE: LH) operates two primary segments-Diagnostics Laboratories and Biopharma Laboratory Services-delivering a broad portfolio that ranges from routine blood chemistry and urinalysis to high-complexity gene-based and esoteric tests, anatomic pathology, pharmacogenetics, and companion-diagnostic development. The company also offers digital platforms for patients and providers, specimen-collection logistics, and drug-development support services, serving a client base that includes pharma/biotech firms, MCOs, hospitals, and agricultural chemical companies.

Key recent metrics underscore the business’s scale and growth trajectory: FY 2023 revenue reached $13.9 billion, with a 7 % year-over-year increase driven largely by specialty-testing volumes and higher-margin biopharma services; operating margin improved to 9.2 % as the firm leveraged automation and digital front-end tools. Core sector drivers include the accelerating adoption of molecular diagnostics (projected CAGR ≈ 12 % through 2028) and sustained reimbursement pressure from Medicare policy reforms, which together shape pricing power and test-mix profitability.

For a deeper quantitative assessment, you may explore ValueRay’s detailed LH valuation model.

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (855.2m TTM) > 0 and > 6% of Revenue (6% = 825.9m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA 3.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 10.53% (prev 11.78%; Δ -1.25pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.10 (>3.0%) and CFO 1.80b > Net Income 855.2m (YES >=105%, WARN >=100%)

Net Debt (5.93b) to EBITDA (2.01b) ratio: 2.95 <= 3.0 (WARN <= 3.5)

Current Ratio 1.55 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (83.7m) change vs 12m ago -0.83% (target <= -2.0% for YES)

Gross Margin 28.45% (prev 27.92%; Δ 0.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 74.66% (prev 68.30%; Δ 6.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.73 (EBITDA TTM 2.01b / Interest Expense TTM 232.5m) >= 6 (WARN >= 3)

Altman Z'' 3.51

(A) 0.08 = (Total Current Assets 4.08b - Total Current Liabilities 2.63b) / Total Assets 18.26b

(B) 0.48 = Retained Earnings (Balance) 8.70b / Total Assets 18.26b

(D) 0.91 = Book Value of Equity 8.66b / Total Liabilities 9.55b

Total Rating: 3.51 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 58.11

1. Piotroski 9.0pt

2. FCF Yield 5.09%

3. FCF Margin 10.03%

4. Debt/Equity 0.75

5. Debt/Ebitda 2.95

6. ROIC - WACC (= 0.86)%

7. RoE 10.20%

8. Rev. Trend -4.84%

9. EPS Trend -60.92%

What is the price of LH shares?

As of December 27, 2025, the stock is trading at USD 253.89 with a total of 248,311 shares traded.
Over the past week, the price has changed by +0.74%, over one month by -5.36%, over three months by -9.28% and over the past year by +11.10%.

Is LH a buy, sell or hold?

Laboratory of America has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy LH.

Strong Buy: 13
Buy: 3
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the LH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	299.7	18%
Analysts Target Price	299.7	18%
ValueRay Target Price	252.6	-0.5%

LH Fundamental Data Overview December 24, 2025

Market Cap USD = 21.20b (21.20b USD * 1.0 USD.USD)
P/E Trailing = 25.0059
P/E Forward = 14.4092
P/S = 1.5398
P/B = 2.4313
P/EG = 1.868
Beta = 0.961
Revenue TTM = 13.77b USD
EBIT TTM = 1.33b USD
EBITDA TTM = 2.01b USD
Long Term Debt = 5.08b USD (from longTermDebt, last quarter)
Short Term Debt = 691.1m USD (from shortTermDebt, last quarter)
Debt = 6.53b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.93b USD (from netDebt column, last quarter)
Enterprise Value = 27.13b USD (21.20b + Debt 6.53b - CCE 598.1m)
Interest Coverage Ratio = 5.73 (Ebit TTM 1.33b / Interest Expense TTM 232.5m)
FCF Yield = 5.09% (FCF TTM 1.38b / Enterprise Value 27.13b)
FCF Margin = 10.03% (FCF TTM 1.38b / Revenue TTM 13.77b)
Net Margin = 6.21% (Net Income TTM 855.2m / Revenue TTM 13.77b)
Gross Margin = 28.45% ((Revenue TTM 13.77b - Cost of Revenue TTM 9.85b) / Revenue TTM)
Gross Margin QoQ = 28.77% (prev 29.66%)
Tobins Q-Ratio = 1.49 (Enterprise Value 27.13b / Total Assets 18.26b)
Interest Expense / Debt = 0.86% (Interest Expense 56.0m / Debt 6.53b)
Taxrate = 22.40% (75.5m / 337.0m)
NOPAT = 1.03b (EBIT 1.33b * (1 - 22.40%))
Current Ratio = 1.55 (Total Current Assets 4.08b / Total Current Liabilities 2.63b)
Debt / Equity = 0.75 (Debt 6.53b / totalStockholderEquity, last quarter 8.70b)
Debt / EBITDA = 2.95 (Net Debt 5.93b / EBITDA 2.01b)
Debt / FCF = 4.30 (Net Debt 5.93b / FCF TTM 1.38b)
Total Stockholder Equity = 8.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.68% (Net Income 855.2m / Total Assets 18.26b)
RoE = 10.20% (Net Income TTM 855.2m / Total Stockholder Equity 8.38b)
RoCE = 9.90% (EBIT 1.33b / Capital Employed (Equity 8.38b + L.T.Debt 5.08b))
RoIC = 7.31% (NOPAT 1.03b / Invested Capital 14.15b)
WACC = 6.45% (E(21.20b)/V(27.73b) * Re(8.23%) + D(6.53b)/V(27.73b) * Rd(0.86%) * (1-Tc(0.22)))
Discount Rate = 8.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.71%
[DCF Debug] Terminal Value 73.37% ; FCFE base≈1.17b ; Y1≈911.1m ; Y5≈590.4m
Fair Price DCF = 128.7 (DCF Value 10.67b / Shares Outstanding 82.9m; 5y FCF grow -26.04% → 3.0% )
EPS Correlation: -60.92 | EPS CAGR: -12.07% | SUE: 0.98 | # QB: 3
Revenue Correlation: -4.84 | Revenue CAGR: -3.39% | SUE: 0.09 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.11 | Chg30d=+0.003 | Revisions Net=-1 | Analysts=11
EPS next Year (2026-12-31): EPS=17.52 | Chg30d=-0.022 | Revisions Net=-1 | Growth EPS=+7.3% | Growth Revenue=+4.4%

Additional Sources for LH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle